Innovent Biologics Stock Current Valuation
| IVBXF Stock | USD 4.85 0.24 4.72% |
Valuation analysis of Innovent Biologics helps investors to measure Innovent Biologics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Innovent Biologics' price fluctuation is relatively risky at this time. Calculation of the real value of Innovent Biologics is based on 3 months time horizon. Increasing Innovent Biologics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Innovent pink sheet is determined by what a typical buyer is willing to pay for full or partial control of Innovent Biologics. Since Innovent Biologics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Innovent Pink Sheet. However, Innovent Biologics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 4.85 | Real 4.32 | Hype 4.85 | Naive 5.5 |
The real value of Innovent Pink Sheet, also known as its intrinsic value, is the underlying worth of Innovent Biologics Company, which is reflected in its stock price. It is based on Innovent Biologics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Innovent Biologics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Innovent Biologics helps investors to forecast how Innovent pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Innovent Biologics more accurately as focusing exclusively on Innovent Biologics' fundamentals will not take into account other important factors: Innovent Biologics Company Current Valuation Analysis
Innovent Biologics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Innovent Biologics Current Valuation | 5.13 B |
Most of Innovent Biologics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Innovent Biologics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Innovent Biologics has a Current Valuation of 5.13 B. This is 64.27% lower than that of the Healthcare sector and 10.48% higher than that of the Biotechnology industry. The current valuation for all United States stocks is 69.13% higher than that of the company.
Innovent Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Innovent Biologics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Innovent Biologics could also be used in its relative valuation, which is a method of valuing Innovent Biologics by comparing valuation metrics of similar companies.Innovent Biologics is currently under evaluation in current valuation category among its peers.
Innovent Fundamentals
| Return On Equity | -0.29 | |||
| Return On Asset | -0.14 | |||
| Profit Margin | (0.68) % | |||
| Operating Margin | (0.78) % | |||
| Current Valuation | 5.13 B | |||
| Shares Outstanding | 1.53 B | |||
| Shares Owned By Insiders | 7.15 % | |||
| Shares Owned By Institutions | 44.34 % | |||
| Price To Book | 4.22 X | |||
| Price To Sales | 1.39 X | |||
| Revenue | 4.27 B | |||
| Gross Profit | 2.98 B | |||
| EBITDA | (2.99 B) | |||
| Net Income | (3.14 B) | |||
| Cash And Equivalents | 8.32 B | |||
| Cash Per Share | 5.67 X | |||
| Total Debt | 2.02 B | |||
| Debt To Equity | 0.29 % | |||
| Current Ratio | 3.21 X | |||
| Book Value Per Share | 6.54 X | |||
| Cash Flow From Operations | (2.02 B) | |||
| Earnings Per Share | (0.32) X | |||
| Number Of Employees | 5.54 K | |||
| Beta | 0.16 | |||
| Market Capitalization | 8.37 B | |||
| Total Asset | 16.24 B | |||
| Z Score | 2.4 | |||
| Net Asset | 16.24 B |
About Innovent Biologics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Innovent Biologics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Innovent Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Innovent Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Innovent Pink Sheet
Innovent Biologics financial ratios help investors to determine whether Innovent Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Innovent with respect to the benefits of owning Innovent Biologics security.